213 related articles for article (PubMed ID: 31980928)
41. Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis.
Kluin-Nelemans HC; Jawhar M; Reiter A; van Anrooij B; Gotlib J; Hartmann K; Illerhaus A; Oude Elberink HNG; Gorska A; Niedoszytko M; Lange M; Scaffidi L; Zanotti R; Bonadonna P; Perkins C; Elena C; Malcovati L; Shoumariyeh K; von Bubnoff N; Müller S; Triggiani M; Parente R; Schwaab J; Kundi M; Fortina AB; Caroppo F; Brockow K; Zink A; Fuchs D; Angelova-Fischer I; Yavuz AS; Doubek M; Mattsson M; Hagglund H; Panse J; Simonowski A; Sabato V; Schug T; Jentzsch M; Breynaert C; Várkonyi J; Kennedy V; Hermine O; Rossignol J; Arock M; Valent P; Sperr WR
Theranostics; 2021; 11(1):292-303. PubMed ID: 33391475
[TBL] [Abstract][Full Text] [Related]
42. Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects.
Vos BJ; van der Veer E; van Voorst Vader PC; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; de Monchy JG; van Doormaal JJ; Oude Elberink JN
J Allergy Clin Immunol; 2015 Mar; 135(3):792-8. PubMed ID: 25129675
[TBL] [Abstract][Full Text] [Related]
43. The Prevalence Of Osteoporosis Is Low in Adult Cutaneous Mastocytosis Patients.
Degboé Y; Severino-Freire M; Couture G; Apoil PA; Gaudenzio N; Hermine O; Ruyssen-Witrand A; Paul C; Laroche M; Constantin A; Livideanu CB
J Allergy Clin Immunol Pract; 2024 May; 12(5):1306-1312. PubMed ID: 38423295
[TBL] [Abstract][Full Text] [Related]
44. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre.
Hermans MAW; Rietveld MJA; van Laar JAM; Dalm VASH; Verburg M; Pasmans SGMA; Gerth van Wijk R; van Hagen PM; van Daele PLA
Eur J Intern Med; 2016 May; 30():25-30. PubMed ID: 26809706
[TBL] [Abstract][Full Text] [Related]
45. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
46. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis.
Zanotti R; Bonifacio M; Lucchini G; Sperr WR; Scaffidi L; van Anrooij B; Oude Elberink HN; Rossignol J; Hermine O; Gorska A; Lange M; Hadzijusufovic E; Miething C; Müller S; Perkins C; Shomali W; Elena C; Illerhaus A; Jawhar M; Parente R; Caroppo F; Solomianyi O; Zink A; Mattsson M; Yavuz AS; Panse J; Varkonyi J; Doubek M; Sabato V; Breynaert C; Vucinic V; Schug T; Hägglund H; Wortmann F; Brockow K; Angelova-Fischer I; Belloni Fortina A; Triggiani M; Reiter A; Hartmann K; Malcovati L; Gotlib J; Shoumariyeh K; Niedoszytko M; Arock M; Kluin-Nelemans HC; Bonadonna P; Valent P
Leukemia; 2022 Feb; 36(2):516-524. PubMed ID: 34545185
[TBL] [Abstract][Full Text] [Related]
47. Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors.
Shomali W; Gotlib J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804174
[TBL] [Abstract][Full Text] [Related]
48. A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis.
Gotlib J; Baird JH; George TI; Langford C; Reyes I; Abuel J; Perkins C; Schroeder K; Bose P; Verstovsek S
Blood Adv; 2019 Aug; 3(15):2264-2271. PubMed ID: 31350306
[TBL] [Abstract][Full Text] [Related]
49. Bone lesions in systemic mastocytosis: Bone histomorphometry and histopathological mechanisms.
Bouvard B; Pascaretti-Grizon F; Legrand E; Lavigne C; Audran M; Chappard D
Morphologie; 2020 May; 104(345):97-108. PubMed ID: 32127247
[TBL] [Abstract][Full Text] [Related]
50. Retinol-binding protein 4 is positively associated with bone mineral density in patients with type 2 diabetes and osteopenia or osteoporosis.
Huang N; Zhou J; Wang W; Wang Q; Tang Y; Sun Y; Wang D; Chen S
Clin Endocrinol (Oxf); 2018 May; 88(5):659-664. PubMed ID: 29394455
[TBL] [Abstract][Full Text] [Related]
51. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome.
Matito A; Morgado JM; Álvarez-Twose I; Sánchez-Muñoz L; Pedreira CE; Jara-Acevedo M; Teodosio C; Sánchez-López P; Fernández-Núñez E; Moreno-Borque R; García-Montero A; Orfao A; Escribano L
PLoS One; 2013; 8(10):e76116. PubMed ID: 24155887
[TBL] [Abstract][Full Text] [Related]
52. Serum chemistry profiling and prognostication in systemic mastocytosis: a registry-based study of the ECNM and GREM.
Lübke J; Schmid A; Christen D; Oude Elberink HNG; Span LFR; Niedoszytko M; Gorska A; Lange M; Gleixner KV; Hadzijusufovic E; Stefan A; Angelova-Fischer I; Zanotti R; Bonifacio M; Bonadonna P; Shoumariyeh K; von Bubnoff N; Müller S; Perkins C; Elena C; Malcovati L; Hagglund H; Mattsson M; Parente R; Varkonyi J; Fortina AB; Caroppo F; Brockow K; Zink A; Breynaert C; Leven T; Yavuz AS; Doubek M; Sabato V; Schug T; Hartmann K; Triggiani M; Gotlib J; Hermine O; Arock M; Kluin-Nelemans HC; Panse J; Sperr WR; Valent P; Reiter A; Schwaab J
Blood Adv; 2024 Jun; 8(11):2890-2900. PubMed ID: 38593217
[TBL] [Abstract][Full Text] [Related]
53. Diagnosis and management of mastocytosis: an emerging challenge in applied hematology.
Valent P
Hematology Am Soc Hematol Educ Program; 2015; 2015():98-105. PubMed ID: 26637707
[TBL] [Abstract][Full Text] [Related]
54. [Histological characteristics and prevalence of secondary osteoporosis in systemic mastocytosis. A retrospective analysis of 158 cases].
Delling G; Ritzel H; Werner M
Pathologe; 2001 Mar; 22(2):132-40. PubMed ID: 11321729
[TBL] [Abstract][Full Text] [Related]
55. Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis.
Henriques A; Muñoz-González JI; Sánchez-Muñoz L; Matito A; Torres-Rivera L; Jara-Acevedo M; Caldas C; Mayado A; Pérez-Pons A; García-Montero AC; Álvarez-Twose I; Orfao A
Blood; 2022 Jan; 139(4):572-583. PubMed ID: 34496018
[TBL] [Abstract][Full Text] [Related]
56. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL).
Horny HP; Sotlar K; Stellmacher F; Valent P; Grabbe J
J Clin Pathol; 2006 Mar; 59(3):264-8. PubMed ID: 16505276
[TBL] [Abstract][Full Text] [Related]
57. Next-generation sequencing in systemic mastocytosis: Derivation of a mutation-augmented clinical prognostic model for survival.
Pardanani A; Lasho T; Elala Y; Wassie E; Finke C; Reichard KK; Chen D; Hanson CA; Ketterling RP; Tefferi A
Am J Hematol; 2016 Sep; 91(9):888-93. PubMed ID: 27214377
[TBL] [Abstract][Full Text] [Related]
58. Assessment of clinical findings, tryptase levels, and bone marrow histopathology in the management of pediatric mastocytosis.
Carter MC; Clayton ST; Komarow HD; Brittain EH; Scott LM; Cantave D; Gaskins DM; Maric I; Metcalfe DD
J Allergy Clin Immunol; 2015 Dec; 136(6):1673-1679.e3. PubMed ID: 26044856
[TBL] [Abstract][Full Text] [Related]
59. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
Jawhar M; Schwaab J; Hausmann D; Clemens J; Naumann N; Henzler T; Horny HP; Sotlar K; Schoenberg SO; Cross NC; Fabarius A; Hofmann WK; Valent P; Metzgeroth G; Reiter A
Leukemia; 2016 Dec; 30(12):2342-2350. PubMed ID: 27416984
[TBL] [Abstract][Full Text] [Related]
60. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
